This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Ecole Des Hautes Etudes En Sante Publique (Ehesp), National Institute of Health and Medical Research, Universitë De Bordeaux. Active years: 2019-2020.
Company Filing History:
2 out of 4 
2 out of 1,853 
2 out of 226 
Years Active: 2019-2020
Title: Robin Flynn: Innovator in Polypeptide Research
Introduction
Robin Flynn is a notable inventor based in Sutton Bonington, GB. He has made significant contributions to the field of biotechnology, particularly in the development of polypeptides. With a total of 2 patents to his name, Flynn's work focuses on reducing CD95-mediated cell motility, which has important implications for medical research and treatment.
Latest Patents
Flynn's latest patents include innovative polypeptides designed to reduce CD95-mediated cell motility. The first patent details a polypeptide with an amino acid sequence that maintains at least 70% identity with the sequence ranging from the amino-acid residue at position 175 to position 191 in SEQ ID NO:1. This invention aims to provide new avenues for therapeutic interventions in diseases where cell motility plays a critical role.
Career Highlights
Throughout his career, Robin Flynn has worked with esteemed institutions such as the National Institute of Health and Medical Research and Université de Bordeaux. His research has contributed to advancements in understanding cell behavior and its implications in various medical conditions.
Collaborations
Flynn has collaborated with notable colleagues in his field, including Patrick Legembre and Pierre Vacher. These partnerships have fostered a collaborative environment that enhances the quality and impact of his research.
Conclusion
Robin Flynn's contributions to polypeptide research exemplify the innovative spirit of modern science. His patents and collaborations reflect a commitment to advancing medical knowledge and therapeutic options.